Wegovy Cost and Savings Card: How to Pay $25, $149 or $349 in 2026

With commercial insurance that covers Wegovy, the manufacturer's savings card can bring your cost down to as little as $25 a month. Without coverage, Novo Nordisk's self-pay prices run from $149 to $399 a month, depending on whether you take the pill or the injection and which dose. The official list price is $1,349 a month, but almost nobody pays that, and it's set to drop to $675 on January 1, 2027.

Which price you'll actually pay depends on one thing: your insurance situation. Here's every route, with the catches.

The savings card isn't a one-time coupon. It's an ongoing Novo Nordisk program with two uses. If your commercial plan covers Wegovy, it lowers your copay to as little as $25 a month, with a maximum benefit of $100 a month. If your copay is $200, for example, you'd pay $100. It applies to every dose, including Wegovy HD. ACA marketplace and federal employee plans count as commercial.

If you're uninsured or your plan doesn't cover Wegovy, the same program gives access to the fixed self-pay prices above through NovoCare Pharmacy and participating retail pharmacies. You can enroll at NovoCare.com or Wegovy.com.

The card can't be used with Medicare, Medicaid, TRICARE, VA or other government plans. People on those plans can still pay the self-pay prices out of pocket.

Wegovy's list price is $1,349.02 a month. It's the number insurers use to calculate deductibles and coinsurance, not what most people pay at the counter. In 2026, Novo Nordisk announced that the list price of its semaglutide medicines will fall to $675 a month on January 1, 2027. That helps insured people whose deductible or coinsurance is tied to the list price. It doesn't change the separate self-pay prices.

GoodRx advertises "Wegovy from $149," but that price applies to the starter doses of the pill, not the pen. For the injection, discount cards typically land far above Novo Nordisk's own $199 and $349 self-pay prices. If your insurance covers Wegovy, use the savings card instead; a discount card usually can't be combined with insurance.

Medicare Part D has historically been barred from covering drugs for weight loss alone. The Medicare GLP-1 Bridge, which runs from July 1, 2026 to December 31, 2027, is an exception: eligible Part D enrollees can get Wegovy (pen, pill or HD), Zepbound or Foundayo for weight management for a $50 monthly copay. It runs through a CMS contractor rather than your Part D plan, requires prior authorization, and the copay doesn't count toward your Part D out-of-pocket limit. Medicare also covers Wegovy when it's prescribed to lower cardiovascular risk in people with heart disease.

On self-pay, the pill is cheaper at the start ($149 for 1.5 mg) and costs $299 at the full 25 mg dose, slightly less than the $349 pen. The two work similarly: in their main trials, Wegovy 2.4 mg injection produced about 15% average weight loss at 68 weeks and the 25 mg pill about 13.6% at 64 weeks. The pill has to be taken every morning on an empty stomach. See our Wegovy dosing guide for both schedules.

Savings cards and cash prices only matter once you know where you stand with your plan. Our guide to whether insurance covers Wegovy walks through employer plans, the 2026 Medicare GLP-1 Bridge pilot at $50 a month, Medicaid by state, what prior authorization checks and how to appeal a denial.

Before paying cash, check whether your plan still covers Wegovy; for Blue plans, see does Blue Cross Blue Shield cover Wegovy.

Wegovy costs as little as $25 a month with commercial coverage and the savings card, $149 to $399 a month self-pay depending on form and dose, and $50 a month for eligible Medicare patients through the GLP-1 Bridge. The $1,349 list price matters mostly for deductibles and drops to $675 in 2027. Start with your insurance status, then pick the program that fits. To compare options, see which GLP-1 is best for weight loss.